头颈部鳞状细胞癌（HNSCC）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 法国头颈部鳞状细胞癌市场预计将从 2025 年的 1.05 亿美元增长到 2035 年的 3.35 亿美元，这反映了在免疫疗法日益普及的推动下，该市场实现了强劲的两位数增长。
• 市场扩张受以下因素支撑：
• 免疫查核点抑制剂（PD-1抑制剂）的广泛应用
• 晚期疾病中联合治疗的广泛应用
• 虽然患者数量相对稳定成长，但市场规模的成长主要受癌症药物高昂成本和治疗时间延长的影响。
• 未来的成长取决于免疫肿瘤学、标靶治疗和旨在提高存活率的个人化治疗策略的进步。

头颈部鳞状细胞癌（HNSCC）概述

头颈部鳞状细胞癌（HNSCC）是一组生物学异质性强、侵袭性高的恶性肿瘤，发生于口腔、咽喉和喉部的黏膜上皮。它是全球最常见的癌症之一，其主要原因是长期接触烟草和酒精，以及感染高危险型人类乳突病毒（HPV）。

HPV阳性头颈部鳞状细胞癌（HNSCC），尤其是口咽癌，常伴随晚期淋巴结转移，与HPV阴性病例相比，预后较好，治疗反应较高，逐渐形成独特的临床亚型。大多数患者确诊时已处于局部晚期，需要多学科综合治疗以尽可能保留功能，包括手术、放射线治疗和含铂类药物类放射线治疗合併放疗。然而，復发率仍然很高，相当一部分患者会发展为復发/转移性疾病（R/M）。

随着PD-1标靶免疫查核点抑制剂的引入，復发/转移性头颈部鳞状细胞癌（R/M HNSCC）的治疗模式发生了显着变化。这些药物构成了治疗的基础，既可作为单一药物治疗，也可与化疗联合治疗。儘管取得了这些进展，但整体预后仍然较差，凸显了开发更有效、更持久的治疗策略的必要性。

主要亮点

• 在美国，预期盛行率（经存活已调整的病例）将从 2025 年的 404,100 例增加到 2035 年的 432,300 例，呈稳定成长趋势（年复合成长率为 0.7%）。
• 高復发率和进展为转移性疾病仍然是主要的临床挑战，晚期的长期存活率有限。
• 免疫疗法和基于生物标记的治疗方法的日益普及，正在极大地改变治疗格局，尤其是在復发和转移的情况下。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准和顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Fulgent Pharma LLC.
• CSPC Megalith Biopharmaceutical Co., Ltd.
• Gilead Sciences
• Merck Sharp &Dohme LLC
• Sichuan Baili Pharmaceutical Co., Ltd.
• Transgene
• Regeneron Pharmaceuticals
• Inhibrx Biosciences, Inc
• AstraZeneca
• Coherus Oncology, Inc.
• Ipsen
• Radiopharm Theranostics, Ltd
• KaliVir Immunotherapeutics
• IDEAYA Biosciences
• ImmunityBio, Inc.
• Rondo Therapeutics
• AbbVie
• Sutro Biopharma, Inc.
• SystImmune Inc.
• Zumutor Biologics Inc.
• Arcus Biosciences, Inc.
• Normunity AccelCo, Inc.

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
• 重点
• 诊断和治疗过程/演算法
• 主要治疗方法概述及KOL洞察
• 新兴治疗方法
• 重点
• 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
• 值得关注的早期研发管线

第六章：未满足的需求与目标产品分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook

Thelansis's "Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Head and Neck Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) is a biologically heterogeneous and highly aggressive group of malignancies arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It represents one of the most prevalent cancers globally and is driven by two primary etiological pathways: chronic exposure to tobacco and alcohol, and infection with high-risk human papillomavirus (HPV).

HPV-positive HNSCC, particularly in the oropharynx, has emerged as a distinct clinical subtype with improved prognosis and greater responsiveness to treatment compared to HPV-negative disease, despite often presenting with advanced nodal involvement. Most patients are diagnosed at a locally advanced stage, requiring multidisciplinary, function-preserving treatment approaches, including surgery, radiation therapy, and platinum-based chemoradiation. However, recurrence rates remain high, with a significant proportion progressing to recurrent or metastatic (R/M) disease.

The treatment paradigm for R/M HNSCC has evolved significantly with the introduction of immune checkpoint inhibitors targeting PD-1, which have become a cornerstone of therapy, either as monotherapy or in combination with chemotherapy. Despite these advances, overall prognosis remains poor, highlighting the need for more effective and durable treatment strategies.

Key Highlights

• In the US, prevalence (survival-adjusted cases) is projected to increase from 404.1K in 2025 to 432.3K by 2035, reflecting steady growth (0.7% CAGR).
• High rates of recurrence and progression to metastatic disease remain a major clinical challenge, with limited long-term survival in advanced stages.
• Increasing adoption of immunotherapy and biomarker-driven treatment approaches is reshaping the therapeutic landscape, particularly in recurrent/metastatic settings.

Market Overview

• The France HNSCC market is projected to grow from $105M in 2025 to $335M by 2035, reflecting strong double-digit growth driven by expanding use of immunotherapies.
• Market expansion is supported by:
• Increased uptake of immune checkpoint inhibitors (PD-1 inhibitors)
• Broader use of combination regimens in advanced disease
• Despite relatively stable patient growth, market value is driven by high-cost oncology therapies and extended treatment duration.
• Future growth will depend on advancements in immuno-oncology, targeted therapies, and personalized treatment strategies to improve survival outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Fulgent Pharma LLC.
• CSPC Megalith Biopharmaceutical Co., Ltd.
• Gilead Sciences
• Merck Sharp & Dohme LLC
• Sichuan Baili Pharmaceutical Co., Ltd.
• Transgene
• Regeneron Pharmaceuticals
• Inhibrx Biosciences, Inc
• AstraZeneca
• Coherus Oncology, Inc.
• Ipsen
• Radiopharm Theranostics, Ltd
• KaliVir Immunotherapeutics
• IDEAYA Biosciences
• ImmunityBio, Inc.
• Rondo Therapeutics
• AbbVie
• Sutro Biopharma, Inc.
• SystImmune Inc.
• Zumutor Biologics Inc.
• Arcus Biosciences, Inc.
• Normunity AccelCo, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)